AOM Infusion Selected as a Limited Distribution Specialty Pharmacy for QIVIGY®, A New Immune Globulin Therapy
AOM Infusion (“AOM”), a leading specialty infusion pharmacy and provider, today announced it has joined Kedrion Biopharma’s limited distribution network for QIVIGY®, a new 10% immune globulin (Ig) liquid indicated for treatment of adults with Primary Humoral Immunodeficiency (PI).
AOM Infusion Among the First to Earn New Immunoglobulin (Ig) Distinction Recognizing Centers of Excellence
AOM Infusion (“AOM”), a leading provider of specialty infusion care and pharmacy services, announced today that it has earned the Distinction in Immunoglobulin (Ig) Therapy from the Accreditation Commission for Health Care (ACHC) in collaboration with the Immunoglobulin National Society (IgNS). This distinction is designed to identify immunoglobulin therapy centers of excellence, and AOM is proud to be among the first infusion therapy providers nationwide to receive it.
AOM Infusion Designated a Limited Distribution Network Specialty Pharmacy for YIMMUGO® Immunoglobulin Replacement Therapy
AOM Infusion (“AOM”), a leading provider of specialty infusion and pharmacy services for chronic and complex conditions, has been selected by Kedrion Biopharma as a limited distribution network specialty pharmacy for YIMMUGO® (Immune Globulin Intravenous, Human-dira, 10%), an immune globulin (Ig) liquid for the treatment of primary humoral immunodeficiency (PI), expanding AOM’s IVIG offerings.
AOM Infusion Named to Inc. 5000 List of America’s Fastest-Growing Companies
AOM Infusion, a leading national provider of specialty infusion and pharmacy services, has been named to the annual Inc. 5000 list, recognizing the nation’s fastest-growing private companies. AOM ranks No. 2,566 based on a three-year revenue growth of 175 percent. The list provides a data-driven snapshot of the most successful companies within the economy’s most dynamic segment—its independent, entrepreneurial businesses.
AOM Infusion Is Now a Limited Distribution Partner of ALYGLO™ Immunoglobulin Replacement Therapy
AOM Infusion, a leading provider of specialty infusion therapy, announced today that it has been selected by GC Biopharma as a limited distribution partner for ALYGLO™, an FDA-approved immunoglobulin replacement therapy indicated for the treatment of primary humoral immunodeficiency (PI). ALYGLO™ uses a novel Cation Exchange Chromatography (CEX) process, which results in extra-purified IVIG.
AOM Infusion Expands Its Presence in the Southwest, Pacific Northwest, and Midwest
AOM Infusion, a leading provider of specialty infusion therapy announced today that it is expanding its presence in Arizona, Michigan, and Washington. AOM is focused on developing strong partnerships with local healthcare providers, health systems, and payors ensuring seamless access to vital infusion therapies across the Southwest, Pacific Northwest, and Midwest. This expansion helps the company care for its growing patient base by providing enhanced access to immunoglobulin, chronic inflammatory, and biologic medications. AOM Infusion's commitment to clinical excellence and patient-centric care will continue to deliver optimal health outcomes and improve quality of life.
Keyur Mehta Appointed Chief Executive Officer of AOM Infusion
AOM Infusion (“AOM” or “the Company”), a leading specialty infusion provider focused on intravenous immunoglobulin (“IVIG”), chronic inflammatory (CID) and specialty infusion therapy, today announced that Keyur Mehta has been named Chief Executive Officer. Christopher York will continue in his position as Chairman of the Company.
